SG11201705559RA - Formulation of mk2 inhibitor peptides - Google Patents
Formulation of mk2 inhibitor peptidesInfo
- Publication number
- SG11201705559RA SG11201705559RA SG11201705559RA SG11201705559RA SG11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA
- Authority
- SG
- Singapore
- Prior art keywords
- formulation
- inhibitor peptides
- peptides
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101190P | 2015-01-08 | 2015-01-08 | |
| PCT/US2016/012650 WO2016112292A1 (en) | 2015-01-08 | 2016-01-08 | Formulation of mk2 inhibitor peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705559RA true SG11201705559RA (en) | 2017-08-30 |
Family
ID=56356475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705559RA SG11201705559RA (en) | 2015-01-08 | 2016-01-08 | Formulation of mk2 inhibitor peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10087225B2 (enExample) |
| EP (1) | EP3242886A4 (enExample) |
| JP (1) | JP2018502860A (enExample) |
| KR (1) | KR20170102900A (enExample) |
| CN (1) | CN107406489A (enExample) |
| AU (1) | AU2016205125A1 (enExample) |
| BR (1) | BR112017014737A2 (enExample) |
| CA (1) | CA2972916A1 (enExample) |
| HK (1) | HK1246807A1 (enExample) |
| MX (1) | MX2017008994A (enExample) |
| RU (1) | RU2017128077A (enExample) |
| SG (1) | SG11201705559RA (enExample) |
| WO (1) | WO2016112292A1 (enExample) |
| ZA (1) | ZA201704495B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2961607C (en) | 2014-09-17 | 2023-03-28 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| KR20200130808A (ko) | 2018-03-13 | 2020-11-20 | 가부시키가이샤 아데카 | 비수전해질 이차전지 |
| WO2021211854A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable formulation of a solution containing tiotropium bromide |
| CN111647088B (zh) * | 2020-06-29 | 2023-05-02 | 东北师范大学 | 细胞渗透短肽tat-hns-3及对炎性疾病的应用 |
| JP2025503581A (ja) | 2022-01-14 | 2025-02-04 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ピリジン含有多環系誘導体、その製造方法及び応用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| IT1203660B (it) | 1982-10-08 | 1989-02-15 | Glaxo Group Ltd | Dispositivi per somministrare farmaci a pazienti e confezione di blister per essi |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2178965B (en) | 1985-07-30 | 1988-08-03 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP3061461A1 (en) * | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| EP2606903B1 (en) | 2007-01-10 | 2016-09-14 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| ES2547229T3 (es) | 2007-08-07 | 2015-10-02 | Purdue Research Foundation | Inhibidores de cinasa y usos de los mismos |
| CN102256613B (zh) * | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| CN102316731B (zh) * | 2008-12-10 | 2016-06-01 | 普渡研究基金会 | 基于细胞渗透性肽的激酶抑制剂 |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20110288036A1 (en) | 2010-05-24 | 2011-11-24 | Cynthia Lander | Methods for Treating or Preventing Vascular Graft Failure |
| JP6031510B2 (ja) | 2011-04-12 | 2016-11-24 | モイライ マトリックス インコーポレイテッド | 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法 |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
| US9102015B2 (en) * | 2013-03-14 | 2015-08-11 | Siemens Energy, Inc | Method and apparatus for fabrication and repair of thermal barriers |
| BR112015025968A2 (pt) * | 2013-04-11 | 2018-01-09 | Univ Vanderbilt | poliplexos |
-
2016
- 2016-01-08 MX MX2017008994A patent/MX2017008994A/es unknown
- 2016-01-08 US US14/991,531 patent/US10087225B2/en not_active Expired - Fee Related
- 2016-01-08 JP JP2017536526A patent/JP2018502860A/ja active Pending
- 2016-01-08 HK HK18106201.2A patent/HK1246807A1/zh unknown
- 2016-01-08 KR KR1020177021042A patent/KR20170102900A/ko not_active Withdrawn
- 2016-01-08 WO PCT/US2016/012650 patent/WO2016112292A1/en not_active Ceased
- 2016-01-08 RU RU2017128077A patent/RU2017128077A/ru not_active Application Discontinuation
- 2016-01-08 CA CA2972916A patent/CA2972916A1/en not_active Abandoned
- 2016-01-08 SG SG11201705559RA patent/SG11201705559RA/en unknown
- 2016-01-08 EP EP16735478.6A patent/EP3242886A4/en not_active Withdrawn
- 2016-01-08 AU AU2016205125A patent/AU2016205125A1/en not_active Abandoned
- 2016-01-08 BR BR112017014737A patent/BR112017014737A2/pt not_active Application Discontinuation
- 2016-01-08 CN CN201680005237.6A patent/CN107406489A/zh active Pending
-
2017
- 2017-07-03 ZA ZA2017/04495A patent/ZA201704495B/en unknown
-
2018
- 2018-08-21 US US16/106,504 patent/US20190031730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016205125A2 (en) | 2017-10-19 |
| HK1246807A1 (zh) | 2018-09-14 |
| JP2018502860A (ja) | 2018-02-01 |
| RU2017128077A (ru) | 2019-02-08 |
| MX2017008994A (es) | 2018-09-18 |
| EP3242886A1 (en) | 2017-11-15 |
| US20190031730A1 (en) | 2019-01-31 |
| CN107406489A (zh) | 2017-11-28 |
| KR20170102900A (ko) | 2017-09-12 |
| WO2016112292A1 (en) | 2016-07-14 |
| US20160200782A1 (en) | 2016-07-14 |
| BR112017014737A2 (pt) | 2018-01-16 |
| EP3242886A4 (en) | 2018-08-29 |
| RU2017128077A3 (enExample) | 2019-09-30 |
| ZA201704495B (en) | 2019-01-30 |
| US10087225B2 (en) | 2018-10-02 |
| AU2016205125A1 (en) | 2017-07-13 |
| CA2972916A1 (en) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| ZA201705527B (en) | TGF-ß INHIBITORS | |
| IL251051B (en) | mk2 inhibitors and their uses | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| IL284236A (en) | Modifications and uses of conotoxin peptides | |
| GB201513010D0 (en) | Novel formulation | |
| SI3288379T1 (sl) | Peptidne sestave in načini uporabe | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| ZA201704495B (en) | Formulation of mk2 inhibitor peptides | |
| GB201514758D0 (en) | Formulation | |
| GB201501004D0 (en) | Inhibitors | |
| PT3173071T (pt) | Formulação de maropitant | |
| GB2540026B (en) | Fragment retentive coating formulation | |
| SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
| GB201506316D0 (en) | Novel peptide | |
| EP3330285A4 (en) | TUMOR-INHIBITING PEPTIDE | |
| ZA201803032B (en) | Pharmaceutical compositions of dimethyl fumarate | |
| IL257803B (en) | Peptide analogs derived from vdac1 | |
| GB201520949D0 (en) | Inhibitors | |
| GB201521771D0 (en) | Formulation | |
| GB201511255D0 (en) | Formulation | |
| GB201509891D0 (en) | Formulation | |
| GB201504211D0 (en) | Use of peptides | |
| GB201502834D0 (en) | Composition of objects | |
| PT3280430T (pt) | Péptido qbp1 para uso na prevenção ou tratamento de perturbação de stress pós-traumático, transtorno de stress agudo e síndrome geral de adaptação |